232 related articles for article (PubMed ID: 30263090)
1. Procarbazine, CCNU and vincristine (PCV) versus temozolomide chemotherapy for patients with low-grade glioma: a systematic review.
Hafazalla K; Sahgal A; Jaja B; Perry JR; Das S
Oncotarget; 2018 Sep; 9(72):33623-33633. PubMed ID: 30263090
[TBL] [Abstract][Full Text] [Related]
2. Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV.
McDuff SGR; Dietrich J; Atkins KM; Oh KS; Loeffler JS; Shih HA
Cancer Med; 2020 Jan; 9(1):3-11. PubMed ID: 31701682
[TBL] [Abstract][Full Text] [Related]
3. Radiotherapy Plus Procarbazine, Lomustine, and Vincristine Versus Radiotherapy Plus Temozolomide for IDH-Mutant Anaplastic Astrocytoma: A Retrospective Multicenter Analysis of the French POLA Cohort.
Esteyrie V; Dehais C; Martin E; Carpentier C; Uro-Coste E; Figarella-Branger D; Bronniman C; Pouessel D; Ciron DL; Ducray F; Moyal EC; Network P
Oncologist; 2021 May; 26(5):e838-e846. PubMed ID: 33524191
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and Safety of Different Postoperative Adjuvant Regimens in Patients with Low-Grade Gliomas: A Network Meta-Analysis.
Dongpo S; Xiaozhuo L; Xin L; Zhengyao Z; Qing W; Fameng Z; Mingming F; Qian H; Mei L; Tong C
World Neurosurg; 2023 Nov; 179():e474-e491. PubMed ID: 37673325
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma.
Bell EH; Zhang P; Shaw EG; Buckner JC; Barger GR; Bullard DE; Mehta MP; Gilbert MR; Brown PD; Stelzer KJ; McElroy JP; Fleming JL; Timmers CD; Becker AP; Salavaggione AL; Liu Z; Aldape K; Brachman DG; Gertler SZ; Murtha AD; Schultz CJ; Johnson D; Laack NN; Hunter GK; Crocker IR; Won M; Chakravarti A
J Clin Oncol; 2020 Oct; 38(29):3407-3417. PubMed ID: 32706640
[TBL] [Abstract][Full Text] [Related]
6. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802.
Shaw EG; Wang M; Coons SW; Brachman DG; Buckner JC; Stelzer KJ; Barger GR; Brown PD; Gilbert MR; Mehta MP
J Clin Oncol; 2012 Sep; 30(25):3065-70. PubMed ID: 22851558
[TBL] [Abstract][Full Text] [Related]
7. The role of initial chemotherapy for the treatment of adults with diffuse low grade glioma : A systematic review and evidence-based clinical practice guideline.
Ziu M; Kalkanis SN; Gilbert M; Ryken TC; Olson JJ
J Neurooncol; 2015 Dec; 125(3):585-607. PubMed ID: 26530261
[TBL] [Abstract][Full Text] [Related]
8. Improvement of functional outcome for patients with newly diagnosed grade 2 or 3 gliomas with co-deletion of 1p/19q - IMPROVE CODEL: the NOA-18 trial.
Wick A; Sander A; Koch M; Bendszus M; Combs S; Haut T; Dormann A; Walter S; Pertz M; Merkle-Lock J; Selkrig N; Limprecht R; Baumann L; Kieser M; Sahm F; Schlegel U; Winkler F; Platten M; Wick W; Kessler T
BMC Cancer; 2022 Jun; 22(1):645. PubMed ID: 35692047
[TBL] [Abstract][Full Text] [Related]
9. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
Wick W; Hartmann C; Engel C; Stoffels M; Felsberg J; Stockhammer F; Sabel MC; Koeppen S; Ketter R; Meyermann R; Rapp M; Meisner C; Kortmann RD; Pietsch T; Wiestler OD; Ernemann U; Bamberg M; Reifenberger G; von Deimling A; Weller M
J Clin Oncol; 2009 Dec; 27(35):5874-80. PubMed ID: 19901110
[TBL] [Abstract][Full Text] [Related]
10. Proposed therapeutic strategy for adult low-grade glioma based on aggressive tumor resection.
Nitta M; Muragaki Y; Maruyama T; Ikuta S; Komori T; Maebayashi K; Iseki H; Tamura M; Saito T; Okamoto S; Chernov M; Hayashi M; Okada Y
Neurosurg Focus; 2015 Jan; 38(1):E7. PubMed ID: 25599276
[TBL] [Abstract][Full Text] [Related]
11. Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951.
Erdem-Eraslan L; Gravendeel LA; de Rooi J; Eilers PH; Idbaih A; Spliet WG; den Dunnen WF; Teepen JL; Wesseling P; Sillevis Smitt PA; Kros JM; Gorlia T; van den Bent MJ; French PJ
J Clin Oncol; 2013 Jan; 31(3):328-36. PubMed ID: 23269986
[TBL] [Abstract][Full Text] [Related]
12. Practice changing mature results of RTOG study 9802: another positive PCV trial makes adjuvant chemotherapy part of standard of care in low-grade glioma.
van den Bent MJ
Neuro Oncol; 2014 Dec; 16(12):1570-4. PubMed ID: 25355680
[TBL] [Abstract][Full Text] [Related]
13. Malignant Transformation of Molecularly Classified Adult Low-Grade Glioma.
Tom MC; Park DYJ; Yang K; Leyrer CM; Wei W; Jia X; Varra V; Yu JS; Chao ST; Balagamwala EH; Suh JH; Vogelbaum MA; Barnett GH; Prayson RA; Stevens GHJ; Peereboom DM; Ahluwalia MS; Murphy ES
Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1106-1112. PubMed ID: 31461674
[TBL] [Abstract][Full Text] [Related]
14. Observation versus radiotherapy with or without temozolomide in postoperative WHO grade II high-risk low-grade glioma: a retrospective cohort study.
Wang J; Yan L; Ai P; He Y; Guan H; Wei Z; He L; Mu X; Liu Y; Peng X
Neurosurg Rev; 2021 Jun; 44(3):1447-1455. PubMed ID: 32529528
[TBL] [Abstract][Full Text] [Related]
15. Management of patients with recurrence of diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline.
Nahed BV; Redjal N; Brat DJ; Chi AS; Oh K; Batchelor TT; Ryken TC; Kalkanis SN; Olson JJ
J Neurooncol; 2015 Dec; 125(3):609-30. PubMed ID: 26530264
[TBL] [Abstract][Full Text] [Related]
16. PCV chemotherapy alone for WHO grade 2 oligodendroglioma: prolonged disease control with low risk of malignant progression.
Weller J; Katzendobler S; Karschnia P; Lietke S; Egensperger R; Thon N; Weller M; Suchorska B; Tonn JC
J Neurooncol; 2021 Jun; 153(2):283-291. PubMed ID: 33932195
[TBL] [Abstract][Full Text] [Related]
17. Analysis of temozolomide resistance in low-grade gliomas using a mechanistic mathematical model.
Ollier E; Mazzocco P; Ricard D; Kaloshi G; Idbaih A; Alentorn A; Psimaras D; Honnorat J; Delattre JY; Grenier E; Ducray F; Samson A
Fundam Clin Pharmacol; 2017 Jun; 31(3):347-358. PubMed ID: 27933657
[TBL] [Abstract][Full Text] [Related]
18. Multidisciplinary management of adult low grade gliomas.
Mariş D; Nica D; Mohan D; Moisa H; Ciurea AV
Chirurgia (Bucur); 2014; 109(5):590-9. PubMed ID: 25375042
[TBL] [Abstract][Full Text] [Related]
19. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.
; Cairncross G; Berkey B; Shaw E; Jenkins R; Scheithauer B; Brachman D; Buckner J; Fink K; Souhami L; Laperierre N; Mehta M; Curran W
J Clin Oncol; 2006 Jun; 24(18):2707-14. PubMed ID: 16782910
[TBL] [Abstract][Full Text] [Related]
20. Patterns of care and outcomes of multi-agent versus single-agent chemotherapy as part of multimodal management of low grade glioma.
Haque W; Verma V; Butler EB; Teh BS
J Neurooncol; 2017 Jun; 133(2):369-375. PubMed ID: 28432588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
